Skip to main content

Table. 1 Demographic characteristics of the studies included

From: Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus

Study, year Location Treatment
arm (n)
HbA1c(%) Male (n) Age (years) BMI (kg/m2) Diabetes duration (years) Treatment duration (months) Leptin (ng/mL)
Takeshita [37] Japan Sitagliptin:28
Mitiglinide:29
6.7 ± 0.6
6.9 ± 0.8
18
19
61.0 ± 13.8
65.8 ± 9.7
24.5 ± 3.8
24.2 ± 4.6
86.4 ± 90
145.2 ± 122.4
4 8.7 ± 6.5
10.5 ± 13.4
Takeshita [38] Japan Vildagliptin:53
Liraglutide:49
8.1 ± 1.2
8.0 ± 0.9
36
35
64.5 ± 12.7
64.9 ± 1.9
24.5 ± 4.6
25.4 ± 4.8
NS 3 8.1 ± 6.9
6.9 ± 5.7
Kato [39] Japan Sitagliptin:10
Glimepiride:10
7.2 ± 0.2
7.3 ± 0.2
6
5
62 ± 4.7
55 ± 6.7
25.6 ± 2.6
26.6 ± 2.5
NS 6 12.6 ± 2.3
10.3 ± 3.0
Matsushima [40] Japan Sitagliptin: 120
Voglibose:121
7.9 ± 1.0
7.8 ± 0.8
72
71
63.2 ± 13.8
63.2 ± 11.6
25.0 ± 4.5
25.1 ± 4.5
NS 3 8.3 ± 6.9
9.0 ± 9.3
Dore [41] American Saxagliptin:21
Placebo:21
7.0 ± 0.8
6.6 ± 0.5
10
14
58.3 ± 5.7
56.4 ± 8.5
32.3 ± 4.2
31.5 ± 4.8
120 3 19.4 ± 3.7
14.1 ± 2.1
Takihata [42] Japan Sitagliptin:17
Luseogliflozin:17
10.0 ± 1.41
0.4 ± 1.0
14
15
52.8 ± 15.5
52.1 ± 15.3
26.8 ± 5.1
26.4 ± 4.8
NS 3 9.1 ± 6.7
7.2 ± 4.7
Takeshita [43] Japan Alogliptin:42
Metfomin:42
7.5 ± 1.07
.4 ± 1.2
29
29
63.8 ± 10.5
63.1 ± 13.1
25.4 ± 6.1
24.4 ± 4.0
122.4 ± 124.8
169.2 ± 156
3 11.2 ± 12.8
8.4 ± 10.7
Schiapaccassa [44] Brazil Vildagliptin:19
Metformin:19
8.0 ± 1.8
7.9 ± 2.0
0
0
39.1 ± 5.3
39.8 ± 7.7
36.0 ± 4.0
38.5 ± 6.1
NS 1 21.9 ± 19.4
25.4 ± 13.3
Awal [45] American Linagliptin:14
Placebo:17
7.1 ± 0.7
7.4 ± 1.0
11
7
61.0 ± 5.0
63.0 ± 6.0
31.2 ± 4.4
30.6 ± 2.9
 ≤ 180 3 21.7 ± 22.8
22.5 ± 12.6
Komorizono [46] Japan Linagliptin:24
Metformin:25
7.0 ± 0.5
7.2 ± 0.8
10
9
49.4 ± 10.8
55.6 ± 10.2
29.7 ± 4.9
27.9 ± 4.1
NS 13 17.7 ± 9.3
18.5 ± 8.2